Abbott Molecular, 106
AbbVie, 20, 25, 109, 113, 153
Abilify (aripiprazole), 12
accountable care organizations (ACOs), 110, 178, 188
active ingredient-based groups, 151
Actonel (risedronate), 103
Actos (pioglitazone), 115
acute myeloid leukemia (AML), 99
Aetna, commercial insurers, 164, 174, 190, 223
affordability, 130, 141, 142, 145, 156, 169
of prescription drugs, 145
up-front of medicine, 154
Affordable Care Act (ACA), 21, 149, 167, 175, 176, 179, 189
Afrezza inhaler, 97
AG-221 (enasidenib), 99
AgaMatrix, 204
Agency for Healthcare Research and Quality (AHRQ), 131
Aggarwal, R, 129
agile supply chain, creating, 229
algorithms, 216, 225, 232
Bayesian, 222, 228
AliveCor, 8, 12, 204
alliance. see also strategic alliances
acquisition continuum, 58
biotech companies, 50
Celgene, 49, 54, 55, 84, 95, 98, 99, 107, 140
contract, 62
contractual, 59
arrangement, 64
pharma companies, 50
transactions, 59
Alnylam
cash raising, 27
financing strategies, 26–28
funding, 26
RNA interference (RNAi) based therapies, 26
Alphabet, 6, 8, 12, 17, 18, 20–22, 37, 84, 85
healthcare portfolio, 18
ALS (amyotrophic lateral sclerosis), 102, 127, 129, 199
Alzheimer's disease, 218
Amazon, 21, 215, 231
American Lung Association, 205
American Society of Clinical Oncologists’ (ASCO) Value Framework, 181
American Telemedicine Association (ATA), 211
accreditation, 211
American Well, 210–212
AmeriDoc, 211
Amgen, 4, 46, 49, 54, 73, 103, 113, 117, 123, 164, 190, 227
amyotrophic lateral sclerosis (ALS), 102, 127, 129
analytics, 219
across biopharma value chain, 227
continuum, 224
descriptive, 224
driven organization, 226
enabled biopharma organization, 241
first organization building, 238
as strategic imperative, 239
analytics (continued)
  changing behaviors, 239, 240
  partner for flexibility, 240, 241
  role in establishing product value, 230
to rethink commercial
  activities, 229–232
anaplastic lymphoma kinase, 106
Anthem, 10, 20, 207, 212
antibiotic
development, 146
inappropriate use, 131
research, 146
Apache Hadoop, 222
Apple, 6, 8–17, 22, 85, 100, 138, 140,
197, 199, 200, 202, 206, 215,
227, 229
Apple iTunes, 11
Apple ResearchKit, 140
Apple Watch, 10–14, 22, 138, 197
Aprecia Pharmaceuticals, 201
artificial intelligence (AI), 25, 222
Aspinall, Mara, 72, 91
AstraZeneca, 49, 76, 78, 84, 104, 108,
114, 123, 128, 134, 163, 164,
199, 203, 227
scheme, 164
Australian Pharmaceutical Benefits
  Advisory Committee
  (PBAC), 180
Avalere/Faster Cures’ Patient Perspective
  Value Framework, 181
Baris, Aris, 227
benefit/cost ratio, 156
beyond the pill, 24, 48, 70, 73, 90, 101,
122, 135, 136, 143, 185, 191,
232, 241
beta thalassemia, 140
biannual price, 149, 152
big data, 198, 215, 219, 221
Bill and Melinda Gates Foundation, 41
Biogen, 4, 49, 56, 127, 128, 199, 207, 213
biomarkers, 6, 8, 10, 13, 19, 22, 50, 70,
72, 75, 77–81, 84, 85, 90, 93,
98, 101, 102, 125, 165, 197,
227, 235
development, 80, 84
targeted medicines, 79
biometric sensor, 219
biopharma, 145
best practices for, 210
digital strategies, 197
  new R & D patient-centric
  models, 197, 198
  optimizing clinical trials, 198, 199
  role of social media in trials, 199,
  200
divesting, 55–56
marketing strategy, 94
organizational models, 187, 188
payer relationships, 185–187
pricing model, 147
strategic alliances, 50–51
dealing for, 56–65
  mission and objectives, 57–58
  monitoring results and
  learning, 64–65
  partner selection, 56–57
  structure, 58–62
drivers and constraints, 47
innovation, 49
meeting commercial needs, 49
vs. acquisition, 53–54
structure considerations, 55
to become analytics experts, multiple
  forces, 217
trust-breakers, 186
value chain, 226
biopharma-payer engagement, 188–192
chronic, high-cost diseases
  and outcomes-based deals, 191
data co-creation with payers leads
to, 192
integrated payers, 191
scaling-up new partnership
  models, 189–191
biopharmaceutical
  companies (see biopharma)
  products, 145
biosensors, 6, 8, 9, 14, 101, 102, 112, 122,
  128, 135, 197, 204, 207
biosimilars
  challenge of, 117
developing, 49
INDEX

from Lilly and Boehringer Ingelheim, 203
value proposition associated with, 159
biotech company/entrepreneurs, 35
business model, 34
commercialization, 44
funding sources, and representative amounts, 25 (see also financing sources)
fundraising, geographic considerations, 33
mergers and acquisitions, 43–44
patient engagement capabilities, 44
R & D support payments, 43
biotechnology industry applications, 5–6
megatrends impact, 6
Biotechnology Innovation Organization (BIO), 228
Blin, Emmanuel, 138
blue biotech, 5
Blue Gene supercomputer, 3
Boniva (ibandronate), 97
Bosley, Katrine, 29, 31
BrainBaseline cognitive software, 140
brand generics, 116–117
loyalty, 100
medicines, 168
models, 94, 103, 104
Brilinta (ticagrelor), 114
Bristol-Myers Squibb, 21, 55, 77, 109, 138, 139, 161
employee engagement initiative, 138–140
goals, 139
program development, 139
globally relevant, 139
internally focused, 139
program launch, 140
storytelling, power of, 139
strategy, 139
budget constraints, 182
discipline, 169
bundled payment, 167, 168
experiments, selected, 168
models, 165, 167
business development, 31
models, 50, 69, 218
business-to-business (B to B) model, 176
Bydureon (XR exenatide), 203
Calico, 6, 12, 17, 18, 20, 22
campaigns, 109, 110
CancerCare, 132
cancer treatment, 75
chemotherapy, 75
radiation therapy, 75
capital preservation, adaptations to, 32–33
capital raising
biotech management teams, 32
strategic decisions, 30–33
pricing and dilution, 31–32
capital, sources, 28
corporate venture capital, 28
CancerCare, 132
capital raising
crossover investment funds, 28
governments and disease foundations grants, 28
larger pharmaceutical/biotechnology companies, collaborations with, 28
public investors, 28
seed stage investors, 28
venture capital firms, 28
cardiometabolic syndrome, 12
CDC (Centers for Disease Control and Prevention), 18, 198
Celgene, 49, 54, 55, 84, 95, 98, 99, 107, 140
Centers for Medicare and Medicaid Services (CMS), 131, 167, 189
Cerezyme (imiglucerase), 117
Charpentier, Emanuelle, 3
chemotherapy, 71, 74, 106
Chick, Stephen, 129
chief data officer (CDO), 239
chief information officer (CIO), 239
chief patient officer, 138, 143, 204
chronic myeloid leukemia, 4, 70, 95
Cigna, 164, 190, 211
Cleveland Clinic, 12, 16, 17, 105, 133
Clinical Commissioning Groups, 180
Clinical Educator Programs, 137  
consent forms, 120  
enhancement, 127  
                   improving, 228, 229  
patient-to-patient communications, 122  
trial optimization, 126  
cloud computing, 16, 221  
cloud-based storage, 216  
collaborations, 192  
combination products, 115  
commercial insurers, 174, 177  
commercial risks, 157  
commercialization costs, 147  
companion diagnostics, 70, 77, 105–107  
competition, 146, 148, 150, 153, 158, 165, 167, 175, 176, 186, 212, 229, 242  
competitors, 105, 128, 146  
consumer attitudes, 102  
centered trends, 206–210  
decision journey, 100  
social media, 208–210  
wearables, 206–208  
empowerment, 69  
Web-driven, 197  
engagement, 110  
focused healthcare loans, 170  
information gaps, 123  
pricing, 94  
research, 96  
content marketing, 110–111  
continuous glucose monitoring (CGM) device, 12  
cost control, 73–74  
cost-effectiveness, 180  
analyses, 182  
cost-of-illness modeling, 170  
cost-sharing, 217  
Coulter, Martin, 129  
Crestor (rosuvastatin), 103, 104  
Crick, Francis, 3, 4  
CRISPR/Cas9 technology, 3, 20  
cross-functional teams, 107, 118, 143, 204  
cultural barriers, 238  
curative therapies, 170  
custom-built IBM apps, 16  
cutting-edge technologies, 51  
CVS Health Corp., 164  
cystic fibrosis, 42, 70, 91, 96, 145  
drugs, 145  
Cystic Fibrosis Foundation, 122, 128, 209  
Dana-Farber Cancer Institute, 170, 206  
data analysis, 217  
analytics, 226, 232  
and analytics challenges, 233  
capabilities, 225  
driven solutions, 218  
generation, 218  
integration, 226, 233–235  
lifestyle, 220  
mining process, 136  
privacy, 86, 236, 237  
quality, 233, 235, 236  
sharing, 81, 88  
data breaches, 207  
Davidovic, David, 221, 222  
debt-financing instruments, 170  
decision-making power, 152  
democratization, 217  
department-specific key performance indicators (KPIs), 138  
Dexcom, 6, 12, 19  
diabetes, 6, 12, 16, 18, 19, 75, 104, 105, 110, 114, 123, 124, 134, 141, 167, 168, 190, 191, 200, 203, 204, 207, 224, 231  
diagnostics developers, 88  
drug developers, deal making between, 89  
digital biomarkers, 72  
digital communications metrics for, 141  
digital engagement tools, 133  
digital ethnography tools, 97
digital health, 146
landscape, 9
opportunities, 6–7
strategies, 197
digital impact on supply chain
management, 200, 201
digital markers, in diabetes, 75
digital medicines, 90
digital precision medicine, 74–75
digital services, scope of, 211, 212
digital technologies, 69
digital tools, 146
digital transformation, of commercial
activities, 201–204
direct-to-consumer (DTC)
advertising, 107
promotion, 134
disease
management services, 112
outcomes, 75
prevention accelerator, 123
DNAxexus, 220, 221
doctor on demand, 211
virtual services, 133
Doudna, Jennifer, 3, 4
3D printing, 201
drug costs, 168
drug developers, 84, 88
drug development, 47, 51, 73, 90, 146
efforts, 24
product approval, 24
drug discovery, 47, 226
drug facts box, 107
drug formulations, 115
drug interactions, 117
drug manufacturers, 168
drug marketing, 106
drug pricing, 55
challenges, 48
decisions, 145
economics of, 146–153
inflation, 109
drug recalls, 96
drug regulators, 90
drug resistance, 76
drug spending, 94
drug therapy, 69
drug-diagnostic
combinations, 71
pairs, 79
drug-resistant microbial infections, 146
drugs targeting, 71
dRX Capital, 6, 200, 213
DTC/direct to consumer spending, 109
dual branding models, 103
dynamic
data market, 233
financing environment, 33
e-consultations, 133
e-patients, 126
economic drivers, 146
economic models, 146
EGFR. see epidermal growth factor receptor (EGFR)
EHRs. see electronic, health records (EHRs)
commercial
electronic
consent process, 121
health records (EHRs), 6, 74, 122, 220
data, 220
employee incentives, 61
employers, 179
ACA strengthened federal government’s role, 179
drive harder bargain with, 179
variance, 179
vertical integration, 180
Entresto (sacubitril/valsartan), 164
enzyme replacement therapies, 60
epacadostat, 107
eParticipants, 129
epidermal growth factor receptor (EGFR), 76
expression, 165
inhibitor, 76, 79
epigenome, 72
epinephrine injection, 145
EpiWatch app, 14
equity capital, 33
ertugliflozin(insulin glargine), 203
European Medicines Agency (EMA), 121, 147
European Patients Academy on Therapeutic Innovation (EUPATI), 123
INDEX 279

Gilead, 54, 94, 105, 109, 153, 161, 163, 164
Gleevec (imatinib), 4, 70, 76
Gleevec (from Novartis), 70
global financial crisis 2008, 30
global organization, 108
global price
band, 159
regulation, 147
GlucoSuccess, 13
GNS Healthcare, 222
golden rice, 5
Google, 8, 11, 12, 17–22, 101, 198, 199, 206, 236
Google Flu Trends (GFT), 18, 236
Google Health, 17, 21
Google mobile apps, 18
Google Play, 11
government-funded systems, 180
Grai, 21, 25, 28, 91
green biotech, 5
group purchasing organizations (GPOs), 162
GSK (Glaxo SmithKline), 18–20, 52, 56, 58, 114, 227
Hack Epilepsy, 51, 124
Harvard Pilgrim’s outcomes-based deal, 169
Harvard Pilgrim Health Care, 190
Harvoni (ledipasvir/sofosbuvir), 94, 105, 109
HCAHPS (Hospital Consumer Assessment of Healthcare Providers and Systems) survey, 131–133, 135
health apps, 8
health data, 189, 207, 215, 216, 218, 219, 221, 236
collected on Apple devices, 13
c Consumer-generated, 6
easily quantified through, 135
volume, variety, and velocity of, 215
health ecosystem, 221
health exchanges, 176
health expenditure, 174
Healthgrades, 131, 208
health insurance, 174
health plans, 174, 176
online shopping for, 176
health technology assessment (HTA), 83
criteria, 147
healthcare, 218
big infotech strategies, 12–21
Alphabet healthcare portfolio, 17–18
Apple and IBM in Japan, 16
Apple, role of, 12–14
Calico partnerships, 20
Galvani bioelectronics, 19–20
Google investments, 20–21
Google search and mayo clinic, 18–19
IBM, role of, 15–16
Medtech and pharma alliances, 16–17
Qualcomm, role of, 14–15
Verily partnerships, 19
Watson partnerships, 17
business model variance, 10
costs, 147
data vectors, 218
data, explosion of, 219
digitization of, 90
infotech, disruption risk from, 8–11
infotechnology initiatives, 8
reimbursement, 218
technology strategies, 11–12
new entrants, 12
wearables, rise and limitations of, 11
transforming forces, 7
value chain, impact of digital solutions, 7
HealthKit software, 6
HealthUnlocked, 128
medicine, 153, 158–159, 163
Herceptin (trastuzumab), 4, 5, 69, 76, 77, 101, 103, 114
Heywood, Ben and Jamie, 127
high drug prices, 147
high-level unity, 180
high-price/high-value product, 156
high-price/low-value product, 156
INDEX

high-value data, 225
Hill, Colin, 222
HIPAA (Health Insurance Portability and Accountability Act), 86, 200, 207, 208
hospitalizations, 170
hospital rankings, 131
human epidermal growth factor receptor 2 (HER2), 70
Human Genome Project, 3
Humira (adalimumab), 113
hypertension management program, 137
IBM, 3, 6, 8, 9, 12, 13, 15–17, 21, 22, 49, 85, 197, 199, 227, 233
devolved apps, 16
IBM Watson, 9, 49, 197, 233
Icahn Institute for Genomics and Multiscale Biology, 218
ICarbonX, 128
Illumina, 21, 84, 91, 227
Immunotherapeutics, 52
incentives, 88
Incivek (telaprevir), 129
Incyle, 107
indication-specific pricing, 166
information technology (IT), 85
infotech companies
customer/end user, 10
economics, 10
product or service, 10
technology, 10
validation, 10
inhaler, 97
initial public offerings (IPOs), 29
US and European biotechnology, 29
innovation, 145, 147, 152, 159, 186, 197, 218
partnership, 200
Institute for Clinical and Economic Review (ICER), 165, 166
insulin autoinjector, 120
insulin pump, 12
intellectual property, 51, 63
intelligent supply chain, 202
InterMountain Healthcare, 73, 74, 178, 206
Internet of Things (IoT) devices, 219
investment, 29, 34, 146, 201, 209, 225, 234, 237. see also potential investor
bankers, 40
Google, 20
in Aurora, 209
in digital health, 22
joint, 19
minority, 58
return on, 234
rising, 95
traditional model, 35
venture, 14
Invokana (canagliflozin), 115
IPO
investors types, 38
dedicated specialist investment funds, 38
generalist investors, 38
journey, 39
shares offered, 38
Iressa (gefitinib), 76–79, 163, 164
Jakafi (ruxolitinib), 126
Janssen, 52, 88, 118, 123, 128, 187
Januvia (sitagliptin), 110, 111, 203
Japan
direct and indirect price controls, 151, 152
generic reimbursement prices, 151
Jardiance (empagliflozin)
Johns Hopkins, 14, 15, 21, 54, 212
Johnson & Johnson, 8, 19, 51, 115
joint steering committee (JSC), 63
joint ventures (JVs), 58
JSC. see joint steering committee (JSC)
Jumpstart Our Business Startups (JOBS) Act, 40–41
Juntado, Ryan, 86
Juvenile Diabetes Research Foundation (JDRF), 124
JVs. see joint ventures (JVs)
INDEX

Kaiser Permanente, 74, 174, 178, 206
Kalydeco (ivacaftor), 42, 70, 96, 104, 128, 209
key account managers (KAMs), 111
key opinion leaders (KOLs), 102
Keytruda (pembrolizumab), 77, 78, 106, 107
killer app, 13

Lantus (insulin glargine), 203
launch strategies, 95, 105, 112, 113
Leukemia and Lymphoma Foundation, 199
leverage, 174
big data, 225
data’s four vectors, enabling tools to, 220
Lilly, 4, 88, 105, 109, 114, 115, 190, 203
Lipitor (atorvastatin), 104, 105
liquid biopsy, 91
loan products, 37
Longman, Roger, 175
low-density lipoprotein (LDL), 104
low-level fragmentation, 180
low-price/high-value product, 156
low-price/low-value product, 156, 157

machine learning, 216, 222
causal, 223
management teams, 219
Managing the 360, 133
Maraganore, John, 26
market intelligence, 100
market research, 100
Massachusetts Institute of Technology, 170
Mathers, Ed, 24
Mayo Clinic, 6, 13, 18, 22, 73, 110, 131, 134, 197, 206, 211
Mazzei, Chris, 239
MDLive, 202, 211
Medicaid, 152
prices, 161
programs, 152
medical apps, 75
benefits, 173
needs, 24
medical science liaisons (MSLs), 102, 111
Medicare, 131, 152, 162, 173, 189
Medidata Solutions, 221
Medscape Professional Network, 210
Medtronic, 6, 12, 15, 16, 18, 204
Memorial Sloan Kettering’s Drug Abacus, 181
Merck Manual, 111, 203, 209
metabolome, 72
Mevacor (lovastatin), 104
M2Gen, 128, 199
microbiome, 83
Microsoft’s Cloud, 21
Miller, Steve, 164
Miller, Tom, 91
mining metadata, 232
mobile
appointment scheduling, 133
electrocardiogram (ECG) device, 8, 12
medical device, 12
technologies, 215
mobile health (mHealth), 8, 90, 200
evolution of, 11
Mount Sinai, 17, 54, 199, 200, 218
MSLs. see medical science liaisons (MSLs)
multi-omics analysis, 83–84
multichannel communications, 109–110
multidisciplinary practice units, 167
multiple forces, 217
multiple myeloma, 85, 95, 99, 181
multiple sclerosis, 75, 98, 128, 199, 207
myelodysplastic syndrome (MDS), 99, 140
Myozyme (alglucosidase alfa), 103

Nadauld, Lincoln, 74
National Academy of Medicine (NAM), 123
National Cancer Institute, 206
National Comprehensive Cancer Network’s Evidence Blocks, 181
National Health Insurance (NHI), 152
National Health Service (NHS), 85, 118, 131, 164, 180, 206
National Health Technology Assessment (HTA) agencies, 180
National Institutes of Health (NIH) research, 3, 84, 124
National Quality Forum (NQF), 128, 199
natural language, 216
Netflix, 231
Neupogen (filgrastim), 113
new drug
and data analytics, 226
and price-sensitive therapy, 191
application filing, 12
distribution platforms, 229
positioning, 114
prelaunch sales expectations, 230
time to discover and develop, 48
new market, 33, 114
and payer power, 175
force increase payer power, 175
science, 98, 99
next-generation sequencing, 74
nondilutive capital, 31
nongovernment US payers, 174
non-small cell lung cancer (NSCLC), 106, 107
Novartis, 4, 6, 14, 19, 22, 49, 56, 60, 70, 83, 109, 114, 116, 128, 164, 181, 190, 200, 213, 227
Novo Nordisk, 105, 110, 111, 120, 124, 203, 213
nurse-staffed call centers, 137
observational studies, 97, 102, 124, 129
off-label therapy, 73
Omada Health, 14, 136, 200
Omnitrope, 116, 117
OnePath program, 134
online discussions sites, 129
online healthcare information, 8
online patient communities, 127
PatientsLikeMe, 9, 102, 121, 127, 207, 208, 213, 215
Online shopping, for health plans, 176
Opdivo (nivolumab), 77, 78, 106, 107, 109
open innovation strategies, 51
alliances with academia, 51
alliances with external venture groups, 51
crowdsourcing, 51
innovation hubs, 51
open-label studies, 96
optimized customer penetration, 115–116
O’Reilly, Michael, 13
Organisation for Economic Co-operation and Development, 147
organizational barriers, 238
organizational structures, 219
Orkambi (lumacaftor/ivacaftor), 42, 70
Orphan Drug Act, 96, 125
Orphan Medicinal Products Committee, 121
Oscar Health, 212
OSE Immunotherapeutics, 52
Otsuka, 12
outcome-based
partnerships, 170, 171
pricing experiments, 170
reimbursement, 164
over-the-counter drugs, 108
Parkinson’s disease, 49, 199
Partners Healthcare, 128, 212
patent protection, 116–117
patient
adherence, 110
centric ecosystem, 135
engagement, 73
initiatives, 130
metrics, 140–142
engagement tools, impact of, 133
friendly delivery systems, 120
identification, 125
insight research, 124–125
management, 80
registries, 127
satisfaction, 131
ratings, 131–132
value pathway
diabetes case, 141
Patient Access and Engagement Report, 132
patient advocacy, 41, 60, 87, 112, 120, 122, 134, 138, 143, 155
patient centricity, 49, 70, 73, 120–122, 129, 138, 141–143, 167, 189, 204, 217
crowdsourcing initiatives, 124
drivers and barriers, 121–122
forces impacting, 122
framework, 121
organization models, 142–143
structure options, 143
organizing for, 138–140
points of care, connecting, 130–135
engagement, biopharma initiatives for, 134–135
patient satisfaction ratings, 131–132
physician/patient dynamics, 132–134
strategies in R & D, 129–130
patient engagement, 21, 44, 73, 90, 120, 123, 124, 130, 132, 133, 138, 140, 144
metrics, 140, 144
Patient Focused Medicines Development Initiative (PFMD), 123
patient journey, 135–138
adherence strategies, 137–138
behavior, drivers and barriers of, 136–137
follow-up surveillance, 135
patient key opinion leaders (KOLs), 120
patient-friendly clinical trials designing, 125–130
patient-reported outcomes (PRO), 90, 97, 122, 124, 126–130, 135, 143, 144, 205, 213
rare disease trials, 125
trial recruitment and retention, 125–126
patient-reported outcomes (PROs), 90, 124
comparative drug effectiveness, 126
PatientsLikeMe, 9, 102, 121, 127–129, 207, 208, 213, 215
alliance strategy, 128
business model evolution, 128
challenges, 129
competitive dynamics, 128
disease-specific registries, 127
focus vs. scale, 129
grants, 128
health data platform, as, 127
partnerships, 128
patient forum to personalized health platform, 127–129
patient-centric care decisions, 127
trial optimization, role in, 127
virtual trials, 127
PatientsLikeMe website, 9
pay-for-performance arrangement, 161
payer engagement strategies, 182–185
geospatial mapping tools, 183
information technology (IT) infrastructure, 183
mapping payers based on behaviors and preferences, 184
strategic payer segmentation and engagement, 184
payer segmentation, 176
payer-driven patient segmentation, 87
Pehl, Michael, 98
performance-based agreements (PBAs), 164
personalized care manager, 134
Pfizer, 51, 58, 83, 97, 104, 106, 108, 109, 114, 117, 118, 123, 166, 199, 201, 205, 209
pharma-biotech alliance, 59
pharmacodynamic marker, 99
Pharmacovigilance Risk Assessment Committee, 121
pharmacy benefit managers (PBMs), 162, 174, 179
drug costs consideration in isolation, 179
problem, 179
profitability, 177
Physician Compare, 208
physician digital trends, 210
physician ratings, 208
platinum glucose sensor, 12
Plavix (clopidogrel), 114
INDEX

P-medicine, 72
point-of-care tools, 137
policymakers, 87, 169
pollution-eating bacteria, 5
Pompe disease, 103
portfolio diversification, 113–114
postmarketing surveillance, 6, 128
potential investor
  factors affecting, 37
    fund age, 37
    future rounds, 37
    investment philosophy, 37
    relevant experience, 37
Pothier, Kristin, 87
Praluent (alirocumab), 61, 73, 153, 190
pre-digital age, 216
precision genomics, for cancer, 74–75
precision marketing, 94, 101
  strategy, 95
precision medicine, 6, 69, 70, 94
  alliances in, 50
  biopharma’s engagement, 89
  commercial challenges, 81–83
  data collection, 86
  diagnostic-driven, 79
  focused start-ups, 91
  forces driving, 76
  genomics-driven, 74
  in practice, 75–78
  infrastructure challenges, 80–81
  molecular-driven, 71, 90
  regulatory challenges, 81
  scientific and clinical challenges, 80
  stakeholder expansion in, 86–87
  targeted prevention strategies, 91
Precision Medicine Initiative, 71, 124
predictive biomarkers, 80
preferred stock, 35–36
Premera Blue Cross, 207
premiums, 152, 176, 179, 224
prescription drugs, 94, 108
  DTC advertising of, 109
  spending, in US, 94
prescriptive analytics, 224
price
  concessions, 152
  control, 152
flexibility
  attributes determining, 158
  product factors determine, 158, 159
models, 160, 161
regulations, in major markets, 149
sensitivity, 152
strategy, 157
  new, deployment of, 163, 164
  setting, 157
private insurance, 146
product
  attributes stakeholders prioritize, 154
  development, 98, 215
  efficacy and safety, 153
  pricing flexibility, 150
  pricing strategy, 153, 165
  safety, 217
  unproven real-world value at
    launch, 153, 156
professional lifestyle coaches, 136
progression-free survival (PFS), 106
Prolia (denosumab), 103
promotion, 59, 107, 109, 110, 114, 134,
  135, 154, 203
PROs. see patient-reported outcomes
  (PROs)
Proscar (finasteride), 114
protein coding regions, 226
proteome, 72, 83
Proteus Digital Health, 12, 197
providers, 178
  financial accountability, 178
  financially at-risk, 178
  vertical integration, 178
public
  financing market, 29
  health crisis, 146
  health systems, 146
  private partnership, 84
Qualcomm
  life ecosystem, 15
  three lines of business, 14–15
  licensing and acquisitions, 15
  platforms, 14
  venture investments, 14
Qualcomm Ventures, 14, 15, 200
INDEX 285

quality of life, 97, 115, 124, 126, 138, 153, 154, 203, 217
quantified self, 122, 235
QuintilesIMS, 233
radio frequency identification, 200
RAND team, 170
rare diseases, 27, 32, 95, 102, 111, 116, 120, 122, 124–126, 128, 129, 140, 144, 169, 170, 198, 199, 208, 209, 213, 227
R & D programs, 216
real-time data, 215, 216
real-time intelligence, 21
real-world data, 218, 219, 230
real-world evidence, 7, 102, 107, 112, 117, 118, 122, 126, 130, 146, 162, 199, 203, 217, 227, 230, 231, 233, 234
real-world value, 218
red biotech, 5
redistributing reimbursement risk, 163
reference pricing decisions, 151
Regeneron Genetics Center (RGC), 227
regional health systems, 174
regional price bands, 159
Reid, Jeffery, 221
reimbursement, 153
delays, 165
Remicade (infliximab), 52, 118
remote monitoring, 132
patient portals, role of, 132
Repatha (evolocumab), 73, 153, 164
ResearchKit software, 6
Revlimid (lenalidomide), 95, 107
rheumatoid arthritis (RA), 222
risk-sharing agreements, 90, 161
Rituxan (rituximab), 4, 5, 76, 103
RNA interference (RNAi)
technologies, 26
Robert Wood Johnson Foundation (RWJF), 128
Roche, 4, 49, 60–62, 72, 76, 77, 79, 88, 97, 103, 107, 114, 222
Roche-Genentech relationship, 61, 62
Sage Bionetworks, 140
salesforce strategies, 111–113
Samsung, 12, 15, 49, 197, 206
Sandoz, 113, 116, 117
Sanofi, 6, 18, 19, 49, 60–62, 84, 97, 103, 105, 114, 117, 120, 125, 126, 138, 143, 166, 190, 203, 204, 209
Sanofi digital portfolio in diabetes, 204
Sanofi Genzyme, 103
Sanofi-Regeneron alliance, 61–62
Sarbanes-Oxley Act, 41
Schadt, Eric, 218
Schleifer, Len, 160
scientific innovation, 145
scientific wellness, 11
segmentation (consumer, physician segments), 102
semiautonomous payer committees, 180
sequencing technology, 227
shared decision making (SDM), 132
shareholders, 27, 31, 35, 39, 44, 60
sharing data, 226
Shaywitz, David, 220
Sherman, Michael, 190
Shire, 124, 125, 134, 209
single payment access (SPA) scheme, 164
Small Business Innovation Research (SBIR) program, 34
small data, 219
smartphones, 206
social content risk assessment, 209
social media, 8, 9, 14, 18, 96, 97, 112, 128, 129, 131, 135, 142, 145, 146, 197, 199, 200, 205, 206, 208, 209, 215, 217, 219, 220, 228, 232
from insight mining to co-creating, 208–210
interactions, 219
sites, 145
Sovaldi (sofosbuvir), 94, 105, 153, 161, 163, 164, 169
specialty drugs, 95
high-priced, 94, 175
report, spending on, 95
specialty pharma companies, 47
specialty therapies, 95
Spence, Pamela, 225
Spritam (levetiracetam), 201
Sprycel (dasatinib), 76
stakeholders, 216, 225
start-up biotech companies, 34, 37
statistical analysis, 170
step-therapy, 73
strategic alliances, 50–51
deal terms, 62
  exclusivity, 63
  financial terms, 63
  governance and dispute resolution, 63
  intellectual property, 63
  responsibilities, 62
scope, 62
term and termination, 63
dealing for, 56–65
mission and objectives, 57–58
monitoring results and learning, 64–65
partner selection, 56–57
structure, 58–62
process, 56
strategic payer engagement, 192, 193
structured data, 219
super-consumers, 217
supply chain, 7, 49, 198, 200, 201, 227, 229, 241
surgery, insurer offering medical coverage, 174
sustainability strategies, 113–118
  addressing challenge of biosimilars, 117, 118
  building the market, 115
  franchise building, 113, 114
  mature strategy, 115
  portfolio diversification, 113, 114
  renewal strategies, 116, 117
Tagrisso (osimertinib), 70, 76
  vs. Iressa (gefitinib), 78
Tarceva (erlotinib), 76, 77
target product profiles (TPPs), 98, 112
targeted
cancer drugs, 69, 103
medicines, 69–71, 77
therapies, 70, 74, 76, 107
taxpayer-funded national, 174
Tecentriq (atezolizumab), 107
technographics, 95, 102, 103, 118
Teladoc, 210, 212
telehealth, 210
  scope of services, 211
telemedicine, effectiveness of, 212
therapeutic innovations, 98
time-based bundled payment approach, 169
tools
  analytics, 239, 240
  Cloud-based analytics, 9
digital, 73, 112, 146, 172, 231
  for outcomes-data capture, 170, 171
  geospatial mapping, 183
  interactive, 106
  predictive, 102
  visual, 224
Toujeo (high-concentration glargine), 203
TPPs. see target product profiles (TPPs)
traditional
  financing model, 32
  pharma pricing practices under pressure, 148
Tradjenta (linagliptin), 115
transatlantic disparity, drug pricing, 146
transcriptome, 72, 83
transportation industries, 215
tumor biomarkers, 80
tumor characterization, 75
Twitter, 208, 215, 232
tyrosine kinase
  Bcr-Abl gene coding, 4
  inhibitor afibercept, 166
UCB, 51, 123, 124, 128, 138
UK’s National Institute for Health and Care Excellence (NICE), 180
undisclosed discounts, 147
unit-based pricing methodology, 147
United Healthcare, 20, 86, 212
INDEX 287

United States
  adopt European-style cost-effectiveness hurdles, 181, 182
  Affordable Care Act (ACA), creating new kinds of payers, 176–178
  employers, 179, 180
  providers, 178
  and European biotechnology capital raised, 30
  initial public offerings (IPOs), 29
drug pricing, 162, 163
drug valuation tools, 155
financing market, 33
Food and Drug Administration (FDA), 147
payer
  Europe, governments, 174
  key types, 174
  nongovernment, 174
  offer prescription drug coverage to, 173
  operate in isolation, 174
  prescription drug coverage to citizens qualify for Medicare, 173
  prioritizing value to control drug costs, 152, 153
  reimbursement, 152
UnitedHealthcare
  bundled payment program in oncology, 169
  commercial insurers, 174
University of Washington, 160
unstructured data, 219, 221, 224
health, 216
urgency in payer community, 167

Value Labs, 165
value leakages, 141
value-added services, 112
value-based contracts, 164
work, 164
value-based healthcare, 73
value-based reimbursement, 165
value-creating event, 32
value-focused price not enough for Entresto, 182
Venter, J. Craig, 3, 84
venture capital-backed companies, 30
venture capitalists, 36, 60
venture philanthropy
  Cystic Fibrosis Foundation (CFF), 42, 122, 128, 209
  model, 209
  Vertex pharmaceuticals, 42
Verb Surgical, 19
Verily, 6, 17–20, 22, 49, 84, 85, 125
Vertex, 25, 42, 70, 96, 122, 128, 129, 209
Veterans Health Administration (VA), 212
Viagra (sildenafil), 114, 166
Victoza (liraglutide), 110, 111, 203
Vioxx (rofecoxib), 96
virgin territory, 166
voting equity securities, 31
Walgreens, 202, 211
Wang, Jun, 128
Watson, James, 3, 17
wearables, 11, 14, 76, 83, 84, 90, 122, 128, 130, 133, 135, 137, 144, 199, 206
  biosensors, 122
  sensors, 72, 74
WebMD, 130, 202, 208, 211
Welldoc, 8, 12
white biotechnology, 5
whole genome sequencing, 86
Wilkins, Maurice, 3, 4
Witty, Andrew, 186
World Health Organization (WHO), 8
Xalkori (crizotinib), 106
X-ray crystallography, 3
YouTube, 101, 210, 228, 232
Zarxio, 113, 117
Zocor (simvastatin), 104